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Abstract
Background: The IFI27 interferon gene expression has been found to be largely increased in rotavirus (RV)-infected
patients. IFI27 gene encodes for a protein of unknown function, very recently linked to epidermal proliferation and
related to the epidermal growth factor (EGF) protein. The EGF is a low-molecular-weight polypeptide that is mainly
produced by submandibular and parotid glands, and it plays an important physiological role in the maintenance of
oro-esophageal and gastric tissue integrity.
Our aim was to determine salivary EGF levels in RV-infected patients in order to establish its potential relationship
with IFI27 increased expression and EGF-mediated mucosal protection in RV infection.
Methods: We conducted a prospective comparative study using saliva samples from 27 infants infected with RV
(sampled at recruitment during hospital admission and at convalescence, i.e. at least 3 months after recovery) and
from 36 healthy control children.
Results: Median (SD) EGF salivary concentration was 777 (529) pg/ml in RV-infected group at acute phase and 356
(242) pg/m at convalescence, while it was 337 (119) pg/ml in the healthy control group. A significant association
was found between EGF levels and hospitalization length of stay (P-value = 0.022; r2 = −0.63).
Conclusions: The salivary levels of EGF are significantly increased during the acute phase of natural RV infection,
and relate to length of hospitalization. Further assessment of this non-invasive biomarker in RV disease is warranted.
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Background
Rotavirus (RV) infection is the most common cause of
severe diarrhoea in children and may cause serious
dehydration that usually requires hospitalization [1]. Pre-
dominantly, but not exclusively, RV infects the terminally
differentiated enterocytes in the small intestine and it
induces mucosal damage, villus atrophy and necrosis of
epithelial cells [2]. RV infection alters the function of the
small intestinal epithelium, resulting in characteristic diar-
rhoea, secondary to enterocyte destruction.
There are currently not reliable specific biomarkers
for RV infection. Identifying new correlates of disease
activity may help in designing new treatments and
more efficacious RV vaccines. Use of saliva as a proxy
indicator of intestinal immunity has been proposed as a
non-invasive source of biomarkers [3]. Salivary IgA has
been recently suggested as a correlate for protection for
norovirus intestinal infection [4].
In a recent whole blood transcriptomic analysis of RV-
infected patients, we reported a 23.7 fold increase in the
expression of the IFI27 gene, an interferon-related gene
with unknown function in the RV infection [5]. More-
over, this gene has recently been associated to the
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epidermal growth factor (EGF) and involved in prolifera-
tion of epithelia [6]. EGF, also known as epithelial
growth factor, is a single chain polypeptide secreted by
the submandibular salivary glands and other exocrine in-
testinal glands. In vivo actions of EGF in the gastrointes-
tinal tract include promoting wound healing and tissue
repair, inducing epithelium proliferation and promoting
differentiation [7]. A significant contribution of salivary
EGF to the maintenance of the integrity of the
oesophageal mucosa has been demonstrated in experi-
mental and clinical settings [8]. Patients with low saliv-
ary EGF levels are predisposed to severe oesophageal
damage by gastro-oesophageal reflux [9].
The aim of the present study was to measure the levels
of EGF in saliva from acute-phase RV-infected children




This is a prospective single-centre case-control study
consisting of the collection of saliva samples and clinical
data from pediatric patients admitted to hospital due to
a RV infection, and age- and gender-matched healthy
controls. A total of 27 patients with RV infection were
prospectively recruited at the Pediatric Department of
Hospital Clínico Universitario of Santiago de Compos-
tela (Spain) during the period 2013–2014, all of them
hospitalized with acute gastroenteritis and with a posi-
tive RV antigen detected in stool. Demographic and clin-
ical data, including fever, vomiting, diarrhoea,
dehydration and total severity scores during entire
period of illness were obtained. During the same period,
36 healthy controls were enrolled in the study.
Saliva samples were collected at recruitment on admis-
sion to the hospital (acute phase) and at convalescence
(at least 90 days after infection) for the RV-infected
group. A single sample was obtained at recruitment for
healthy controls group.
The saliva sample was obtained from unstimulated
sublingual saliva using oral swabs (Whatman; Maidstone,
Kent, UK) placed under the tongue for 5 min. The swabs
were eluted in 0.4 ml of phosphate buffered saline (PBS),
and then centrifuged at 800 g for 10 min to remove
mucin and epithelial cells. Supernatants were stored at
−30 °C prior to analysis.
Clinical data collection
Temperature, number of vomiting episodes per day and
duration of vomiting, the severity of diarrhoea (numbers
of stools per day, duration of diarrhoea, and level of de-
hydration), length of hospital stay, and total symptoms
scores measured using Vesikari’s score were registered in
RV-infected subjects.
Detection of EGF in saliva samples
EGF detection assay was carried out using Milliplex
Map human cytokine detection kit (Merck Millipore,
Billerica, MA), following manufacturer indications.
Assays were carried out on a Luminex™ 200 platform.
Statistical analysis
Data are expressed as median and interquartile range.
Statistical analyses were performed using the statistical
software R v.3.1.1 (http://www.r-project.org). Outliers
were identified as those values falling above or below
boxplot whiskers, and eliminated from further analysis.
Non-parametric statistics were used for analysis because
data were not normally distributed in the cohort of
cases. Wilcoxon rank-sum tests were used for compari-
son between acute-phase versus convalescence samples
and versus healthy controls. Spearman’s rank correlation
coefficients were used to quantify the association be-
tween EGF concentration and disease clinical parame-
ters. Reported P-values were below the Bonferroni
significant threshold.
Results
Patients in the RV-infected group ranged in age from 1
to 40 months (median of 12.5 months) at recruitment.
Healthy control children ranged in age from 6 to
7 months (median of 7 months). Demographic and clin-
ical characteristics are summarized in Tables 1 and 2.
Median levels for EGF in saliva from acute-phase RV-
infected patients were 777 (SD = 529) pg/ml. Salivary EGF
Table 1 Demographic characteristics of the study patients








n 27 23 36
Age [months (SD)] 12.5 (1–40) 18 (5–47) 7 (6–7)
Sex (male:female) 16:11 14:9 18:18
Table 2 Clinical characteristics of patients in acute phase
expressed as mean (SD)
Clinical data RV acute-phase
Vesikari’s score 11.07 (3.485)
Length of stay in hospital (days) 5.750 (3.026)
Temperature (°C) 38.70 (0.622)
Number of vomiting episodes per day 3.179 (4.738)
Duration of vomiting (days) 2.037 (1.931)
Number of stools per day 4.929 (5.018)
Duration of diarrhoea (days) 4.571 (2.168)
Level of dehydration 1.607 (1.100)
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levels where significantly lower in convalescent patients
(356 pg/ml; SD = 242; Wilconxon test, P-value = 0.015)
and healthy controls (337 pg/ml; SD = 119; Wilconxon
test, P-value = 0.001474); Fig. 1a. These variations in EGF
levels were not age-related (Fig. 1b).
When assessing possible correlations between EGF
levels and clinical variables in RV infected subjects, a
significant negative correlation was found between sal-
ivary EGF concentration and length of hospital stay
(P-value = 0.022; r2 = −0.63). We did not find any
other significant association between EGF levels and
other clinical parameters of disease (Fig. 1c).
Discussion
In a previous whole blood transcriptomic analysis [5]
carried out in RV-infected patients vs control children, a
remarkable over-expression of IFI27 gene was reported.
IFI27 belongs to the family of interferon inducible genes,
and recently it has been associated to epidermal prolifer-
ation and EGF [6]. In addition, IFI27 was previously
identified as a marker of epithelial cancers and psoriatic
lesions [10] and related to systemic lupus erythematosus
(SLE) [11]. However, the exact role of IFI27 in the RV
infection physiopathology is still unknown, although
based on our results we can suggest that RV infection
might activate an interferon-mediated mechanism of
mucosal recovery after infection damage through a path-
way mediated by IFI27. The observed association be-
tween IFI27 expression and EGF requires a more in-
depth analysis, and the mechanistic approach needs to
be clarified.
EGF is linked to epithelia regeneration after mucosal
lesions, promoting mucosal wound healing and tissue re-
pair [12]. Previous studies in neonatal pigs infected with
RV already pointed to a beneficial role of high physio-
logical levels of EGF in stimulating recovery of epithe-
lium in the small intestine following infection [13]. EGF
application in the mucosa can promote intestinal prolif-
eration and improve restoration after intestinal injury,
Fig. 1 a Values of EGF measured in saliva from RV-infected patients
during acute phase (n = 27) and convalescence (n = 23), and in
healthy controls (n = 36). Saliva samples were tested for EGF using
multiplex cytokine analysis as described in the text. Results are
presented as median and interquartile range EGF levels in pg/ml.
A non-parametric Wilcoxon test was used to determine statistical
significance between acute-phase and convalescence samples.
Mann-Whitney tests were used for comparison between acute-
phase and healthy controls. P-values indicated on graphs are <0.05
(*) and <0.0001 (***). b Association between salivary EGF level and
length of hospitalization stay. Salivary EGF levels and symptom
scores for 27 RV-infected patients were analysed as described in the
text. No other significant association was detected. Spearman’s rank
correlation coefficient (r2) is presented (P-value = 0.022). c Age and
salivary EGF levels. No association was observed between EGF level
and age
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and it might be an effective treatment against intestinal
ischemia-reperfusion injury in rats [14]. The hypothesis
of EGF supplementation after intestinal injury as a po-
tential treatment for improving outcome in patients has
been put forward by other authors based on animal
studies [15]. This finding might lay the ground for a new
recovery treatment after RV infection.
Our present study shows that salivary levels of EGF
are increased during natural RV infection and that they
may correlate with the severity of the disease in terms of
length of hospital stay. The over-expression of EGF
levels in infected patients might suggest a host recovery
response to the damage induced by RV in the intestinal
mucosa. The disruption in the normal homeostasis of
mucosa would induce the production of EGF, also
expressed in the submandibular salivary glands, in order
to restore the integrity of mucosa after infection.
Interestingly, we found that the higher the levels of
EGF in acute-phase samples from RV-infected patients
upon admission, the shorter the length of stay in hos-
pital. It could be argued that the greater level of EGF re-
flects a more powerful response of mucosal homeostasis,
thus facilitating a faster recovery, and a reduction in the
length of hospitalization. This association, if prospect-
ively confirmed, might allow to make predictions on re-
covery of mucosal integrity and hospitalization length
with a simple and non-invasive methodology. The use of
saliva as a non-invasive proxy for intestinal immunity
after enteric infection opens the door to the search for
new specific biomarkers for RV infection that might cor-
relate with clinical parameters of disease.
One limitation of the present study is the limited
number of individual analysed, however the novelty of
our findings merits consideration and further confirma-
tory studies. Another limitation derives from the differ-
ent localization of previous gene expression analyses
(performed in whole blood), and our EGF quantification
(performed in the epithelial mucosa).
Conclusions
In conclusion, RV infection induces an increased pro-
duction of EGF by submandibular glands that could be
associated to IFI27 gene over-expression. Moreover, in-
creased salivary EGF concentrations were found to be
associated with length of hospitalization. Further studies
to corroborate our findings are needed. In the meantime,
we can postulate saliva as a good proxy to advance in
our knowledge of RV infection.
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